Exploiting the EBV-MS Link to Quell Secondary Progressive Disease

Adoptive immunotherapy targeting EBV-infected B cells was safe and improved symptoms in a case study of secondary progressive MS

Adoptive immunotherapy that targets the immune system response to EBV-infected B cells helped...

Clinical Research

Editors' Pick

Comprehensive Immunophenotyping of Cerebrospinal Fluid Cells in Patients with Neuroimmunological Diseases.

Han S, Lin Y C, Wu T, Salgado AD, Mexhitaj I, Wuest SC, Romm E, Ohayon J, Goldbach-Mansky R, Vanderver A, et al.

J Immunol. 2014 Feb 7. PMID: 24510966. Abstract

MS Research Roundup: February 7, 2014

Latest Myelin-Repair Candidate; Crowdsourcing Clinical Trials; Fingolimod Pregnancy Caution; Japan Neuroimmunology Meeting News

Items of interest to multiple sclerosis researchers from around the Web...

Clinical Research, Drug Development, Meetings, Methods

Papers: 31 Jan 2014 - 7 Feb 2014

Check out this week's papers from PubMed. If you are a member, please log in to recommend and comment on papers. If you are not a member, please register today and join the conversation.

Editors' Pick

Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study.

Bergvall N, Makin C, Lahoz R, Agashivala N, Pradhan A, Capkun G, Petrilla AA, Karkare SU, Balderston McGuiness C, Korn JR

PLoS One. 2014; 9(2):e88472. Epub 2014 Feb 06. PMID: 24516663. Abstract

MS Research Roundup: February 5, 2014

Clinical Trial Data Open to Scientists; Innate Immunity in Progressive MS; Paying for MS Drugs

Items of interest to multiple sclerosis researchers from around the Web...

Clinical Research, Drug Development, Laboratory Research

Editors' Pick

Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis.

Pender MP, Csurhes PA, Smith C, Beagley L, Hooper KD, Raj M, Coulthard A, Burrows SR, Khanna R

Mult Scler. 2014 Feb 3. PMID: 24493474. Abstract

Editors' Pick

Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis.

Sand I K, Krieger S, Farrell C, Miller AE

Mult Scler. 2014 Feb 3. PMID: 24493475. Abstract

CSF Metabolite Analysis May Offer Sensitive Biomarkers for MS

The systematic study of the complement of small-molecule metabolites in the CSF suggests altered energy and phospholipid metabolism in MS and may yield quantitative biomarkers

Systematic study of the complement of small molecule metabolites, known as metabolomics, suggests...

Laboratory Research

Editors' Pick

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.

Leist TP, Comi G, Cree BAC, Coyle PK, Freedman MS, Hartung H-P, Vermersch P, Casset-Semanaz F, Scaramozza M, oral cladribine for early MS(ORACLE MS) Study Group

Lancet Neurol. 2014 Mar; 13(3):257-67. Epub 2014 Feb 04. PMID: 24502830. Abstract

Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

User Top Menu

Exploiting the EBV-MS Link to Quell Secondary Progressive Disease

MS Research Roundup: February 7, 2014

Papers: 31 Jan 2014 - 7 Feb 2014

MS Research Roundup: February 5, 2014

CSF Metabolite Analysis May Offer Sensitive Biomarkers for MS

Pages

MSDF Footer

Search form

Papers: 31 Jan 2014 - 7 Feb 2014

Pages